巨细胞动脉炎与风湿性多肌痛患者对SARS-CoV-2疫苗的体液免疫应答:基础接种后抗体衰减及加强针效果
该随访研究纳入既往接受基础接种的巨细胞动脉炎(GCA)/风湿性多肌痛(PMR)患者,于基础接种后6个月(n=24)和加强接种后1个月(n=46)采血,并与年龄、性别及疫苗匹配的对照(分别为n=58和n=42)比较。结果显示GCA/PMR患者抗体浓度随时间下降快于对照,且与基础接种期间泼尼松龙治疗相关;加强接种后抗体浓度患者与对照相当,基础接种后抗体浓度(而非加强时治疗)可预测加强后抗体水平。作者强调对基础接种反应差者重复加强接种的重要性。
要点
- GCA/PMR患者基础接种后抗体衰减快于对照,与基础接种期间泼尼松龙治疗相关。
- 加强接种后抗体浓度患者与对照相当。
- 基础接种后抗体浓度低者单次加强后仍处免疫劣势。
核心结论
- 基础接种后体液免疫衰减与泼尼松龙治疗相关,而加强接种后的抗体升高与泼尼松龙治疗无关。
- 基础接种后抗体浓度低的患者单次加强接种后仍处于免疫劣势。
- 作者强调对基础接种反应差的患者重复加强接种的重要性。
研究设计与样本
- 随访研究,纳入既往参加基础接种(BNT162b2或ChAdOx1)研究的GCA/PMR患者,基础接种后6个月采血n=24,加强接种(BNT162b2或mRNA1273)后1个月采血n=46。
- 对照为年龄、性别及疫苗匹配者,分别n=58和n=42。
- 采用多元线性回归,以加强后抗体浓度为因变量,基础接种后抗体、泼尼松龙>10mg/天及甲氨蝶呤使用为预测变量。
主要发现
- GCA/PMR患者抗体浓度随时间下降快于对照,且与基础接种期间泼尼松龙治疗相关。
- 加强接种后抗体浓度在患者与对照间相当。
- 基础接种后抗体浓度可预测加强接种后抗体浓度,而加强接种期间的治疗不能预测。
临床怎么用
- 作者强调对基础接种反应差的患者重复加强接种的重要性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Vaccination remains essential in preventing morbidity of SARS-CoV-2 infections. We previously showed that >10 mg/day of prednisolone and methotrexate was associated with reduced antibody concentrations after primary vaccination in patients with giant cell arteritis (GCA) and polymyalgia rheumatica (PMR). This follow-up study was undertaken to measure the decay of antibody concentrations and the immunogenicity of SARS-CoV-2 booster vaccination. METHODS: Patients with GCA/PMR included in the primary vaccination (BNT162b2 [Pfizer-BioNTech] or ChAdOx1 [Oxford/AstraZeneca]) study were asked again to donate blood samples 6 months after primary vaccination (n = 24) and 1 month after booster vaccination (n = 46, BNT162b2 or mRNA1273). Data were compared to those of age-, sex-, and vaccine-matched controls (n = 58 and n = 42, respectively). Multiple linear regression was performed with post-booster antibody concentrations as dependent variable and post-primary vaccination antibodies, prednisolone >10mg/day, and methotrexate use as predicting variables. RESULTS: Antibody concentrations decreased faster over time in GCA/PMR patients than in controls, which was associated with prednisolone treatment during primary vaccination. Post-booster antibody concentrations were comparable between patients and controls. Antibody concentrations post primary vaccination, but not treatment during booster vaccination, were predictive for antibody concentrations post booster vaccination. CONCLUSION: These results indicate that the decay of humoral immunity after primary vaccination is associated with prednisolone treatment, whereas the subsequent increase after booster vaccination, was not. Patients with low antibody concentrations following primary vaccination remained at an immunogenic disadvantage after a single booster vaccination. This longitudinal study in GCA/PMR patients stresses the importance of repeated booster vaccination for patients with poor responses to primary vaccination.
引用
- van Sleen Y, van der Geest KSM, Buisman AM, et al. Humoral SARS-CoV-2 Vaccine Responses in Patients With Giant Cell Arteritis and Polymyalgia Rheumatica: Decay After Primary Vaccination and Effects of the Booster. Arthritis Care Res (Hoboken). 2023. PMID: 37332051. doi:10.1002/acr.25173
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。